Effect of the If channel blocker ivabradine on the parameters of external respiration function in patients with chronic obstructive pulmonary disease in its stable course period


如何引用文章

全文:

详细

Aim. To evaluate the effect of the If channel blocker ivabradine on bronchial patency and the volume parameters of external respiration function in patients with chronic obstructive pulmonary disease (COPD) in remission in order to determine whether the drug may be used in patients with coronary heart disease (CHD) concurrent with COPD.
Subjects and methods. Heart rate, bronchial patency, and lung volume were studied by body plethysmography in 59 patients with COPD before and 14 days after administration of ivabradine in a daily dose of 10 mg.
Results. The If channel blocker ivabradine that is a highly selective bradycardiac agent fails to affect the velocity and volume parameters of external respiration function, thus it may be used to treat CHD concurrent with COPD.
Conclusion. The If channel blocker ivabradine exerts no effect on external respiration function parameters (bronchial patency, volume parameters) and it can find clinical use in the treatment of angina pectoris and chronic heart failure in patients with CHD concurrent with COPD.

参考

  1. Kobinger W. Specific bradycardic agent, a new approach to therapy in angina pecto ris? Progr. Pharmacol. 1985; 5: 89- 100.
  2. Simon L., Ghaleh B., Puybasset L. et al. Coronary and haemodynamic effects of SI6257, a new bradycardic agent, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther. 1995. 275: 659-666.
  3. Heidland U. E., Strauer B. E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001. 104: 1477-1482.
  4. Borer J. S. Drug insight: If inhibitors as specific heart-rate-reducing agents. Nat. Clin. Pract. Cardiovasc. Med.: 2004; 1: 103-109.
  5. Colin P., Ghaleh B., Monnet X. et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J. Pharmacol. Exp. Ther. 2004. 308: 236-240.
  6. Tattersfield A. E. Respiratory function in the elderly and the effects of beta block ade. Cardiovasc. Drugs Ther. 1991; 4 (suppl. 6): 1229-1232.
  7. Lewis R. V., Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs: an update. Drug Saf. 1993; 9: 272-279.
  8. Ramahi T. M. Beta-blocker therapy for chronic heart failure. Am. Fam. Physician. 2000; 62: 2267-2274.
  9. Reneland R., Alvarez E., Andersson P. E. et al. Induction of insulin resistance by beta blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J. Hum. Hypertens. 2000; 14: 175-180.
  10. Krone W., Nagele H. Effects of antihypertensives on plasma lipids and lipo protein metabolism. Am. Heart J. 1988; 16: 1729-1734.
  11. Frishman W. H., Sica D. A. Calcium channel blockers. In: Frishman W. H. et al., eds. Cardiovascular pharmacotherapies. 2nd ed. New York: McGrew-Hill; 2003. 105-130.
  12. Moore N., Joannidés R., Iacob M. et al. Effects of a pure bradycardic agent, SI6257, at rest and during exercise in healthy volunteers: comparison with propranolol. Br. J. Clin. Pharmacol. 1998; 45: 188-189.
  13. Borer J. S., Fox K., Jaillon P. et al. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multi-centered, placebo-controlled trial. Circulation 2003; 107: 817-823.
  14. Brown S. M., Dubin A. E., Chaplan S. R. The role of pacemaker currents in neuropathic pain. Pain Pract. 2004; 4: 182-193.
  15. Васюк Ю. А. Новые возможности лечения больных ишемической болезнью сердца и бронхиальной астмой. Consilium Medicum 2007; 9 (5): 10.
  16. Игнатова Г. Л., Соколова Н. И. Сложности лечения больного с сочетанной патологией ХОБЛ и ИБС. Пульмонология. Избран. вопр. 2004; 24: 6-7.
  17. Rosen M. R., Bucchi A., Robinson R. B. If modulation: perspectives in clinical medicine. Eur. Heart K. Suppl. 2007; 8 (suppl. DPp): D3-D8.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2010

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##